N-Acetylcysteine Therapy

Primary Indication: Acetaminophen Overdose

The American College of Medical Toxicology recommends administering N-acetylcysteine (NAC) immediately when acetaminophen overdose is known or suspected, ideally within 8-10 hours of ingestion but still beneficial up to 24 hours 1
NAC should be administered immediately if acetaminophen levels plot in the possible or probable risk zones on the Rumack-Matthew nomogram 1
Treatment should be initiated even when acetaminophen history is uncertain but suspected based on clinical presentation 1
The standard dosing protocols for NAC include an oral regimen of 140 mg/kg loading dose, followed by 70 mg/kg every 4 hours for 17 doses, and an intravenous regimen of 150 mg/kg loading dose over 15 minutes, followed by 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours 1

The American Gastroenterological Association strongly recommends NAC for all patients with acetaminophen-associated acute liver failure 2
NAC reduces mortality in acetaminophen-related acute liver failure (relative risk 0.65, 95% CI 0.43-0.99) 2

The American Gastroenterological Association recommends considering NAC administration in non-acetaminophen acute liver failure, especially when the cause is indeterminate 2
NAC improves transplant-free survival (41% versus 30%, OR 1.61, 95% CI 1.11-2.34, P=0.01) and overall survival benefit (76% versus 59%, OR 2.30, 95% CI 1.54-3.45, P<0.0001) in non-acetaminophen acute liver failure 3

Chronic alcoholics may develop toxicity at lower acetaminophen doses and should receive NAC even if levels are below typical treatment thresholds 1
Fasting patients are at increased risk and may warrant NAC at lower acetaminophen levels 1, 4

The overall incidence of adverse effects with NAC is low, with nausea/vomiting <5%, skin rash <5%, and bronchospasm 1-2% 3

The European Association for the Study of the Liver (EASL) recommends NAC administration immediately in cirrhotic patients with suspected paracetamol-induced liver injury, in addition to stopping the drug 5, 6
Cirrhotic patients, particularly those who are malnourished or actively drinking alcohol, are at higher risk of paracetamol hepatotoxicity even at therapeutic doses 5, 6
In severe alcoholic hepatitis, combination therapy with corticosteroids plus NAC improved 1-month survival compared to corticosteroids alone, according to the Journal of Hepatology 7

NAC is strongly recommended for acetaminophen-associated acute liver failure with demonstrated mortality reduction, as stated by the Gastroenterology journal 8
The EASL guidelines on alcohol-related liver disease do not recommend NAC for routine cirrhosis management, only mentioning it for paracetamol toxicity 5, 6
The American Association for the Study of Liver Diseases (AASLD) and EASL suggest that NAC may benefit non-acetaminophen acute liver failure, particularly in early hepatic encephalopathy stages, although the evidence is not as strong 8

For pregnant women with acetaminophen-associated acute liver failure, N-acetylcysteine (NAC) is strongly recommended and reduces mortality (relative risk 0.65, 95% CI 0.43-0.99) 9

For non-acetaminophen acute liver failure during pregnancy, NAC should be considered, particularly in early stages of hepatic encephalopathy, as recommended by the American Gastroenterological Association 9

The American Society of Hematology suggests that NAC may have a role as a cofactor to enhance reduction in methemoglobinemia in pregnancy, although its use is not well-established 10

Oral NAC at standard dosing (600–1200 mg twice daily) is generally well tolerated; gastrointestinal symptoms are the most frequent adverse events but occur at rates comparable to placebo in randomized trials【11】【12】.
Large‑scale randomized studies across various indications confirm that oral NAC does not increase the overall incidence of adverse events relative to control treatment【13】.

The conventional 20‑hour intravenous NAC regimen is associated with an anaphylactoid reaction rate of approximately 10 %, typically manifesting within the first hour of infusion and requiring prompt recognition and management【11】【12】.

In the PANTHEON trial (n≈1,000 patients with chronic obstructive pulmonary disease), adverse events were reported in 29 % of participants receiving oral NAC versus 26 % of those receiving placebo; serious adverse events were similar between groups (48 vs 46)【13】.
Across multiple COPD trials, the proportion of adverse effects attributed specifically to NAC did not differ from that observed with placebo, reinforcing its favorable safety profile【13】.